[A clinical evaluation of CS-807 in patients with urinary tract infections].
CS-807 is a new cephalosporin orally available. The clinical efficacy and safety of this drug were evaluated in 13 patients with urinary tract infection, including 3 with simple cystitis and 10 with complicated infections. According to the response criteria defined by the Japanese UTI committee, the clinical effectiveness in 8 patients with complicated urinary tract infections regarded evaluable was excellent in 2, moderate in 4 and poor in 2, the overall efficacy rate being 75.0%. Only 1 of the 13 patients studied, developed temporary diarrhea as a drug related adverse reaction.
Nakajima
K
K
Department of Urology, School of Medicine, Kanazawa University.
Oshinoya
Y
Y
Uchibayashi
T
T
Ohkawa
M
M
Hisazumi
H
H
D000328:Adult; D000368:Aged; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D015296:Ceftizoxime / Q000031:analogs & derivatives*; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D003556:Cystitis / Q000188:drug therapy; D003967:Diarrhea / Q000139:chemically induced; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy*; D000097627:Cefpodoxime Proxetil
D000892:Anti-Infective Agents, Urinary; D015296:Ceftizoxime; D002511:Cephalosporins; D000097627:Cefpodoxime Proxetil